Stories

Mark Williams named chief strategy officer for the Knight Cancer Institute

October 21, 2016

Today OHSU announced Mark B. Williams has accepted the role of chief strategy officer for the OHSU Knight Cancer Institute. This is a new position focused on overseeing the budget and long-term financial sustainability of the Knight Cancer Institute.

Breaking new ground in cancer research

June 16, 2016

The 320,000 square foot Knight Cancer Institute research building will house up to 600 researchers, administrators dedicated to cancer research

Knight Cancer Institute funds 13 cancer research projects statewide

June 09, 2016

The Knight Cancer Institute at OHSU has awarded grant funding to 13 community-led projects around the state in the latest funding cycle for its Community Partnership Program. Organizations receiving funding in this round include: The Next Door, Inc., ...

Couple with Oregon ties creates $5 million scholars fund for cancer research

February 02, 2016

Pat and Stephanie Kilkenny establish fund within the Knight Cancer Institute at OHSU to honor three distinguished mentors, support graduate student research.

New leads in the struggle against a formidable leukemia

December 04, 2015

A coordinated push to decrypt a complex form of leukemia is delivering a trove of new drug candidates and treatment ideas, a dozen of which will be presented at the American Society of Hematology Annual Meeting in Orlando, Florida (Dec. 5-8).

What really makes cancer drug ‘super responders’ exceptional survival stories?

November 09, 2015

Reports of “super responders” – patients who do exceptionally well on a cancer treatment –may be driving unfounded assumptions about the effectiveness of the drugs involved, researchers caution.

Kidney cancer’s genomic drivers revealed

November 04, 2015

A massive search involving cancer researchers across the U.S. and Canada has revealed many of the altered genes and cell signaling pathways that drive a poorly understood form of kidney cancer, primary papillary renal cell carcinoma.

Media’s frequent use of superlative terms to describe new cancer drugs questioned by study

October 29, 2015

While most new cancer drugs afford modest benefits, approved drugs or those in development may be heralded as “game changers” or “breakthroughs” in the lay press

Leukemias with ALK mutations identified, may respond to ALK inhibitors

June 01, 2015

Columbia Memorial Hospital, OHSU collaborate to expand cancer treatment services in Astoria

May 09, 2015

Radiation therapy will soon be available close to home for people living at the mouth of the Columbia River.

Stories

OHSU in the News